Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

Syndicated from the fediverse. Read and engage on the original instance.

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00350-X/fulltextOpen link View original on kbin.social

Comments1

1 reply

rehabdoll

lemmy.world

That’s pretty fucking cool

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial | Spyke